Previously, we have evaluated the association between GnRH agonist use and increased hemoglobin A1c (HbA1c) levels and worsening control of lipid levels in men with preexisting type 2 diabetes (E. Lin, unpublished data, 2022).8 Increased risk of hypertension, another important risk factor for CVD, has been observed in men with PCa treated with GnRH agonists.9 However, data are inconsistent on the association between GnRH agonists and hypertension. The gene discussed is GNRH1; the disease is hypertensive disorder.